Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast

Ming Xu1,2, Jin-Hua Lu1, Ya-Zhen Zhong1

  • 1Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, China.

Frontiers in Oncology
|April 21, 2022
PubMed
Abstract

Insights

Triple-negative breast cancer (TNBC) patients can be classified into three subtypes based on damage-associated molecular patterns (DAMPs). This DAMPs subtyping system predicts prognosis and response to immunotherapy, offering potential for precision cancer medicine.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
  • Damage-associated molecular patterns (DAMPs) and immunogenic cell death (ICD) influence immunotherapy outcomes in TNBC.
  • Identifying predictive biomarkers is crucial for effective TNBC treatment strategies.

Purpose of the Study:

  • To develop a DAMPs gene signature for classifying TNBC patients.
  • To predict prognosis and immunotherapy response based on DAMPs-driven subtypes.
  • To explore genomic alterations associated with DAMPs subtypes in TNBC.

Main Methods:

  • K-means clustering was employed to identify DAMPs-associated subtypes in 330 TNBC samples.
  • Immune status, genomic alterations, and predicted immunotherapy outcomes were compared across subtypes.
  • The developed subtyping system was validated using the TCGA cohort.

Main Results:

  • Three TNBC subtypes were identified: nuclear DAMPs, inflammatory DAMPs, and DAMPs-suppressed.
  • The inflammatory DAMPs subtype showed the most favorable survival, while the DAMPs-suppressed subtype had the worst prognosis.
  • The inflammatory subtype demonstrated the highest predicted response rate to immunotherapy.

Conclusions:

  • A novel ICD-associated DAMPs subtyping system for TNBC was established.
  • DAMPs expression serves as a potential biomarker for guiding immunotherapy strategies.
  • This subtyping system may facilitate the development of novel immunomodulators and precision immunotherapy for TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
689
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K